3 results
Compare Progression Free Survival (PFS) for brivanib versus placebo in subjects with advanced solid tumors with FGF-2 over-expression and who have obtained stable disease after 12 weeks of treatment with brivanib separately for each tumor.
Primary objectiveTo identify specific genes in the NO pathway that are turned on or off by inactivity. The results will disclose key-genes in the NO pathway relevant for vascular adaptations. Secondary objectiveTo correlate functional vascular…
The purpose of this study is to find answers for the following questions:1. Is BARRX ablation a good alternative to step-wise radical endoscopic resection for patients with a Barrett*s esophagus with high-grade dysplasia or early cancer in terms of…